Pancreatic Cancer Research

ResearcherNordic Bioscience (Denmark)Active in the last 2 years

Nicholas Willumsen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5207-5173; OpenAlex author ID A5049099295. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 11

  1. BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target. Co-author DOI 10.1038/s41598-025-24463-0↗
  2. Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ducta… Last author DOI 10.1186/s12885-025-14283-w↗
  3. High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fmolb.2023.1158058↗
  4. Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibro… Last author DOI 10.3390/biom12091315↗
  5. Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14030819↗
  6. Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer. Last author DOI 10.3390/cells11233763↗
  7. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenoc… Last author DOI 10.1002/ijc.33551↗
  8. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidas… Last author DOI 10.1186/s12967-021-02701-z↗
  9. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. First author DOI 10.1002/ijc.32751↗
  10. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Co-author DOI 10.1038/s41598-019-56268-3↗
  11. Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. Co-author DOI 10.1186/1471-2407-13-554↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. M.A. Karsdal · 11 shared papers, 2013–2025 · strength 1.52
  2. Julia Sidenius Johansen · 8 shared papers, 2020–2025 · strength 1.25
  3. Inna Markovna Chen · 8 shared papers, 2020–2025 · strength 1.25
  4. Lars Nannestad Jørgensen · 6 shared papers, 2021–2025 · strength 0.98
  5. Hadi M. H. Diab · 6 shared papers, 2021–2025 · strength 0.98
  6. Carsten Palnæs Hansen · 6 shared papers, 2020–2025 · strength 0.94
  7. Neel Ingemann Nissen · 6 shared papers, 2021–2025 · strength 0.92
  8. Rasmus S. Pedersen · 4 shared papers, 2022–2025 · strength 0.72
  9. Astrid Zedlitz Johansen · 4 shared papers, 2020–2023 · strength 0.54
  10. Emilie A. Madsen · 2 shared papers, 2022–2023 · strength 0.31
  11. Song Wang · 1 shared paper, 2021 · strength 0.16
  12. Per Pfeiffer · 1 shared paper, 2020 · strength 0.10
  13. Allan Lipton · 1 shared paper, 2019 · strength 0.08
  14. Nelson S. Yee · 1 shared paper, 2019 · strength 0.08
  15. Anne‐Christine Bay‐Jensen · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.